A large-scale analysis of genetic variants within putative miRNA binding sites in prostate cancer

Cancer Discovery

Volumn 5, Issue 4, 2015, Pages 368-379

  Stegeman, Shane ^a   Amankwah, Ernest ^b   Klein, Kerenaftali ^c   O’Mara, Tracy A ^c   Kim, Donghwa ^b   Lin, Hui Yi ^b   Permuth Wey, Jennifer ^b   Sellers, Thomas A ^b   Srinivasan, Srilakshmi ^a   Eeles, Rosalind ^d,e   Easton, Doug ^f   Kote Jarai, Zsofia ^d   Al Olama, Ali Amin ^f   Benlloch, Sara ^f   Muir, Kenneth ^g   Giles, Graham G ^h,i   Wiklund, Fredrik ^j   Gronberg, Henrik ^j   Haiman, Christopher A ^k   Schleutker, Johanna ^l,m   Nordestgaard, Børge G ⁿ   Travis, Ruth C ^o   Neal, David ^p   Pharoah, Paul ^f   Khaw, Kay Tee ^q   Stanford, Janet L ^r,s   Blot, William J ^t   Thibodeau, Stephen ^u   Maier, Christiane ^v   Kibel, Adam S ^w,x   Cybulski, Cezary ^y   Cannon Albright, Lisa ^z   Brenner, Hermann ^aa   Kaneva, Radka ^ab   Teixeira, Manuel R ^ac   Spurdle, Amanda B ^c   Clements, Judith A ^a   Park, Jong Y ^b   Batra, Jyotsna ^a   Cook, Margaret ^ad   Morgan, Angela ^ae   Lophatananon, Artitaya ^ae   Fisher, Cyril ^ae   Leongamornlert, Daniel ^ae   Saunders, Edward J ^ae   Sawyer, Emma J ^ae   Govindasami, Koveela ^ae   Tymrakiewicz, Malgorzata ^ae   Guy, Michelle ^ae   Livni, Naomi ^ae   Wilkinson, Rosemary ^ae   Jugurnauth Little, Sara ^ae   Hazel, Steve ^ae   Dadaev, Tokhir ^ae   Pedersen, John ^ad   Hopper, John L ^ad   Southey, Melissa C ^ad   Karlsson, Ami ^ad   Cavalli Bjoerkman, Carin ^ad   Johansson, Jan Erik ^ad   Adolfson, Jan ^ad   Aly, Markus ^ad   Broms, Michael ^ad   Stattin, Paer ^ad   Henderson, Brian E ^ad   Schumacher, Fredrick ^ad   Auvinen, Anssi ^ad   Taari, Kimmo ^ad   Maeaettaenen, Liisa ^ad   Kujala, Paula ^ad   Murtola, Teemu ^ad   Tammela, Teuvo L J ^ad   Wahlfors, Tiina ^ad   Roder, Andreas ^ad   Iversen, Peter ^ad   Klarskov, Peter ^ad   Nielsen, Sune F ^ad   Weischer, Maren ^ad   Key, Tim J ^ad   Wallinder, Hans ^ad   Gustafsson, Sven ^ad   Donovan, Jenny L ^ad   Hamdy, Freddie ^ad   George, Anne ^ad   Lane, Athene ^ad   Marsden, Gemma ^ad   Davis, Michael ^ad   Brown, Paul ^ad   Pashayan, Nora ^ad   Holt, Sarah ^r   Signorello, Lisa B ^ad   Zheng, Wei ^ad   Wang, Liang ^ad   Tillmans, Lori ^ad   Riska, Shaun ^ad   Rinckleb, Antje ^ad   Herkommer, Kathleen ^ad   Luedeke, Manuel ^ad   Vogel, Walther ^ad   Wokozorczyk, Dominika ^ad   Lubiski, Jan ^ad   Kluzniak, Wojciech ^ad   Dieffenbach, Aida K ^ad   Stegmaier, Christa ^ad   Arndt, Volker ^ad   Zachariah, Babu ^af   Park, Hyun ^af   Pow Sang, Julio ^af   Rincon, Maria ^af   Radlein, Selina ^af   Vlahova, Aleksandrina ^ad   Mitkova, Atanaska ^ad   Slavov, Chavdar ^ad   Kachakova, Darina ^ad   Popov, Elenko ^ad   Christova, Svetlana ^ad   Dikov, Tihomir ^ad   Mitev, Vanio ^ad   Lose, Felicity ^ag   Santos, Joana ^ah   Barros Silva, Joao ^ah   Paulo, Paula ^ah   Pinto, Pedro ^ah   Henrique, Rui ^ah   Maia, Sofia ^ah   Risbridger, Gail ^ai   Taylor, Renea ^ai   Tilley, Wayne ^aj   Butler, Lisa ^aj   Horvath, Lisa ^ak   Yeadon, Trina ^a,al   Eckert, Allison ^a,al   Wood, Glen ^am   Heathcote, Peter ^am   Malone, Greg ^am   Kerr, Kris ^an   Turner, Megan ^an   Collins, Angus ^an   more..

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g UNIVERSITY OF WARWICK   (United Kingdom)

^h CANCER EPIDEMIOLOGY CENTRE   (Australia)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j KAROLINSKA INSTITUTE   (Sweden)

^k UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^l UNIVERSITY OF TURKU   (Finland)

^m TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

ⁿ GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^o UNIVERSITY OF OXFORD   (United Kingdom)

^p UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^q UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^r Fred Hutchinson Cancer Research Center   (United States)

^s UNIVERSITY OF WASHINGTON   (United States)

^t INTERNATIONAL EPIDEMIOLOGY INSTITUTE   (United States)

^u MAYO CLINIC   (United States)

^v UNIVERSITY HOSPITAL ULM   (Germany)

^w BRIGHAM AND WOMEN S HOSPITAL   (United States)

^x WASHINGTON UNIVERSITY   (United States)

^y POMERANIAN MEDICAL UNIVERSITY   (Poland)

^z UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^aa GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^ab MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^ac UNIVERSITY OF PORTO   (Portugal)

^ad Porto University ^*

^ae UKGPCS   (United Kingdom)

^af Moffitt Pease and Lim Cardiology   (United States)

^ag APCB   (Australia)

^ah PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^ai MONASH UNIVERSITY   (Australia)

^aj Adelaide Cancer Centre   (Australia)

^ak GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^al Australian Prostate Cancer Research Centre   (Australia)

^am Brisbane Urology Clinic   (Australia)

^an SULLIVAN NICOLAIDES PATHOLOGY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN 3; MICRORNA; MICRORNA 3162; MICRORNA 370; PROSTATE SPECIFIC ANTIGEN; SYNAPTOBREVIN; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; MESSENGER RNA; VAMP8 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ADULT; ALLELE; ARTICLE; BINDING AFFINITY; CANCER RISK; CONTROLLED STUDY; GENE INTERACTION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PROSTATE CANCER; PROTEIN EXPRESSION; QUANTITATIVE TRAIT LOCUS; REPORTER GENE; RNA BINDING; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION; VALIDATION PROCESS; WESTERN BLOTTING; AGED; BINDING SITE; CANCER GRADING; CANCER STAGING; CASE CONTROL STUDY; CHEMISTRY; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC VARIATION; GENETICS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR;

3' UNTRANSLATED REGIONS; ADULT; AGED; ALLELES; BINDING SITES; CASE-CONTROL STUDIES; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VARIATION; GENOTYPE; HUMANS; KALLIKREINS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUANTITATIVE TRAIT LOCI; R-SNARE PROTEINS; RNA, MESSENGER;

EID: 85000352081     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-1057     Document Type: Article

References (51)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci 2006; 11: 1388-413.
3. Bratt O. What should a urologist know about hereditary predisposition to prostate cancer? BJU Int 2007; 99: 743-7; discussion 7-8.
4. Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 2013; 45: 385-91, 91e1-2.
5. Al Olama AA, Kote-Jarai Z, Berndt SI, Conti DV, Schumacher F, H an Y, et al. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet 2014; 46: 1103-9.
6. Kiriakidou M, Tan GS, Lamprinaki S, De Planell-Saguer M, Nelson PT, Mourelatos Z. An mRNA m7G cap binding-like motif within human Ago2 represses translation. Cell 2007; 129: 1141-51.
7. Pillai RS, Bhattacharyya SN, Artus CG, Zoller T, Cougot N, Basyuk E, et al. Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science 2005; 309: 1573-6.
8. Zinovyev A, Morozova N, Nonne N, Barillot E, Harel-Bellan A, Gorban AN. Dynamical modeling of microRNA action on the protein translation process. BMC Syst Biol 2010; 4: 13.
9. Huang S, Wu S, Ding J, Lin J, Wei L, Gu J, et al. M icroRNA-181a modulates gene expression of zinc finger family members by directly targeting their coding regions. Nucleic Acids Res 2010; 38: 7211-8.
10. Greve TS, Judson RL, Blelloch R. microRNA control of mouse and human pluripotent stem cell behavior. Annu Rev Cell Dev Biol 2013; 29: 213- 39.
11. Lemons D, Maurya MR, Subramaniam S, Mercola M. Developing microRNA screening as a functional genomics tool for disease research. Front Physiol 2013; 4: 223.
12. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005; 102: 13944-9.
13. Fonseca-Sanchez MA, Perez-Plasencia C, Fernandez-Retana J, Arechaga-Ocampo E, Marchat LA, Rodriguez-Cuevas S, et al. micro- RNA-18b is upregulated in breast cancer and modulates genes involved in cell migration. Oncol Rep 2013; 30: 2399-410.
14. Pinho FG, Frampton AE, Nunes J, Krell J, Alshaker H, Jacob J, et al. Downregulation of microRNA-515-5p by the estrogen receptor modulates sphingosine kinase 1 and breast cancer cell proliferation. Cancer Res 2013; 73: 5936-48.
15. Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell 2009; 136: 586-91.
16. Carlsson J, Helenius G, Karlsson M, Lubovac Z, Andren O, Olsson B, et al. Validation of suitable endogenous control genes for expression studies of miRNA in prostate cancer tissues. Cancer Genet Cytogenet 2010; 202: 71- 5.
17. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 2007; 67: 6130-5.
18. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 2009; 136: 642-55.
19. Muckstein U, Tafer H, Hackermuller J, Bernhart SH, Stadler PF, Hofacker IL. Thermodynamics of RNA-RNA binding. Bioinformatics 2006; 22: 1177-82.
20. Pelletier C, Weidhaas JB. MicroRNA binding site polymorphisms as biomarkers of cancer risk. Expert Rev Mol Diagn 2010; 10: 817- 29.
21. Liang D, Meyer L, Chang DW, Lin J, Pu X, Ye Y, et al. Genetic variants in MicroRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response. Cancer Res 2010; 70: 9765- 76.
22. Liu J, Huang J, He Y, Liu J, Liao B, Liao G. Genetic variants in the integrin gene predicted microRNA-binding sites were associated with the risk of prostate cancer. Mol Carcinog 2014; 53: 280-5.
23. Bao BY, Pao JB, Huang CN, Pu YS, Chang TY, Lan YH, et al. Polymorphisms inside microRNAs and microRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy. Clin Cancer Res 2011; 17: 928-36.
24. Kote-Jarai Z, Amin Al Olama A, Leongamornlert D, Tymrakiewicz M, Saunders E, Guy M, et al. Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. Hum Genet 2011; 129: 687-94.
25. Welter D, MacArthur J, Morales J, Burdett T, Hall P, Junkins H, et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations . Nucleic Acids Res 2014; 42: D1001-6.
26. Batra J, Lose F, O'Mara T, Marquart L, Stephens C, Alexander K, et al. Association between Prostinogen (KLK15) genetic variants and prostate cancer risk and aggressiveness in Australia and a meta-analysis of GWAS data. PLoS One 2011;6:e26527.
27. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239- 43.
28. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, d e Bakker PI. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 2008; 24: 2938-9.
29. Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res 2009; 37: W600-5.
30. Thomas LF, Saito T, Saetrom P. Inferring causative variants in micro- RNA target sites. Nucleic Acids Res 2011; 39: e109.
31. Barenboim M, Zoltick BJ, Guo Y, Weinberger DR. MicroSNiPer: a web tool for prediction of SNP effects on putative microRNA targets. Hum Mutat 2010; 31: 1223-32.
32. Stark MS, Tyagi S, Nancarrow DJ, Boyle GM, Cook AL, Whiteman DC, et al. Characterization of the melanoma miRNAome by deep sequencing. PLoS One 2010; 5: e9685.
33. Persson H, Kvist A, Rego N, Staaf J, Vallon-Christersson J, Luts L, et al. Identification of new microRNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene. Cancer Res 2011; 71: 78-86.
34. Chen J, Yao D, Li Y, Chen H, He C, Ding N, et al. Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. Int J Mol Med 2013; 32: 557-67.
35. Thorsen K, Schepeler T, Oster B, Rasmussen MH, Vang S, Wang K, et al. Tumor-specific usage of alternative transcription start sites in colorectal cancer identified by genome-wide exon array analysis. BMC Genomics 2011; 12: 505.
36. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 2008; 68: 6162- 70.
37. Kote-Jarai Z, Olama AA, Giles GG, Severi G, Schleutker J, Weischer M, et al. Seven prostate cancer susceptibility loci identified by a multistage genome-wide association study. Nat Genet 2011; 43: 785-91.
38. Samaan S, Lichner Z, Ding Q, Saleh C, Samuel J, Streutker C, et al. Kallikreins are involved in an miRNA network that contributes to prostate cancer progression. Biol Chem 2014; 395: 991-1001.
39. Lawrence MG, Lai J, Clements JA. Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. Endocr Rev 2010; 31: 407-46.
40. Thorek DL, Evans MJ, Carlsson SV, Ulmert D, Lilja H. Prostatespecific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles. Thromb Haemost 2013; 110: 484-92.
41. Stege R, Grande M, Carlstrom K, Tribukait B, Pousette A. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clin Cancer Res 2000; 6: 160-5.
42. Fortier AH, Nelson BJ, Grella DK, Holaday JW. Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst 1999; 91: 1635-40.
43. Fortier AH, Holaday JW, Liang H, Dey C, Grella DK, Holland-Linn J, et al. Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo. Prostate 2003; 56: 212-9.
44. Mattsson JM, Valmu L, Laakkonen P, Stenman UH, Koistinen H. Structural characterization and anti-angiogenic properties of prostatespecific antigen isoforms in seminal fluid. Prostate 2008; 68: 9 45-54.
45. Mattsson JM, Narvanen A, Stenman UH, Koistinen H. Peptides binding to prostate-specific antigen enhance its antiangiogenic activity. Prostate 2012; 72: 1588-94.
46. Ho YH, Cai DT, Huang D, Wang CC, Wong SH. Caspases regulate VAMP-8 expression and phagocytosis in dendritic cells. Biochem Biophys Res Commun 2009; 387: 371-5.
47. Behrendorff N, Dolai S, Hong W, Gaisano HY, Thorn P. Vesicleassociated membrane protein 8 (VAMP8) is a SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) selectively required for sequential granule-to-granule fusion. J Biol Chem 2011; 286: 29627-34.
48. Zong H, Wang CC, Vaitheesvaran B, Kurland IJ, Hong W, Pessin JE. Enhanced energy expenditure, glucose utilization, and insulin sensitivity in VAMP8 null mice. Diabetes 2011; 60: 30-8.
49. Zhu D, Zhang Y, Lam PP, Dolai S, Liu Y, Cai EP, et al. Dual role of VAMP8 in regulating insulin exocytosis and islet beta cell growth. Cell Metab 2012; 16: 238-49.
50. Shiffman D, Rowland CM, Louie JZ, Luke MM, Bare LA, Bolonick JI, et al. Gene variants of VAMP8 and HNRPUL1 are associated with early-onset myocardial infarction. Arterioscler Thromb Vasc Biol 2006; 26: 1613-8.
51. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005; 33: e179.